Neuromodulation Devices Market Set To Grow To $6.53 Bn By 2021

08 August 2018
Pharma

Visiongain has launched a new Pharmaceutical Report: Neuromodulation Devices Report 2017-2027: Revenue Forecasts for Deep Brain Stimulation, Spinal Cord, Vagus Nerve, Sacral Nerve and Gastric Electrical Applications

The report forecasts the neuromodulation devices market will multiply in revenues from 2017 to 2027. The pharmaceutical segment is evolving. Visiongain reports the strength of the neuromodulation devices market is its spinal cord stimulation segment, which generated revenues of $1.89bn. Growth in the market will be driven by the ageing population and the increasing prevalence of age-related conditions and chronic diseases. This will drive demand from both the developing and the developed world for neuromodulation devices. In addition, better access to healthcare and new diagnostic techniques has increased the number of people being identified with conditions such as chronic pain, and increase the number of patients receiving adequate treatment. Continuous research and development will lead to more applications being found for neuromodulation devices, with an increasing trend for more-personalised healthcare. All these factors combined will drive the growth of the neuromodulation devices industry through to 2027.

‘’Neuromodulation devices provide promising treatments for illnesses including chronic pain, epilepsy, Parkinson’s disease, depression and incontinence. The neuromodulation devices market is set to experience growth over the next 10 years, driven by the ageing population and the increasing prevalence of age-related conditions and chronic diseases and better access to healthcare. Continuous research and development will lead to more applications being found for neuromodulation devices, with an increasing trend for more-personalised healthcare.
The US will retain its position as market leader, emerging countries such as China and India will also contribute to the growth of the industry as they strive to provide better healthcare, thus increasing sales of neuromodulation devices.’’ – Medical Device Industry Analyst

The new report shows revenue forecasts to 2027 at overall world market, submarket and national level. It forecasts these world-level submarkets:

• Spinal Cord Stimulation
• Sacral Nerve Stimulation
• Vagus Nerve Stimulation
• Deep Brain Stimulation
• Gastric Electric Stimulation

This investigation research, data and analyses covering activities of Medtronic, Boston Scientific
St Jude Medical (Subsidiary of Abbott Diagnostics), Cyberonics (Subsidiary of LivaNova).

Analyses cover R&D, Mergers and Acquisitions, and commercial news and predicts revenues to 2027 in leading regional markets. This includes the US, Japan, Germany, the UK, France, Italy, Spain (EU5 group), Brazil, Russia, India, China.

Neuromodulation Devices Report 2017-2027 adds to visiongain’s range of reports on industries and markets in healthcare. Together these studies cover medical devices, diagnostics and pharmaceuticals.

Leading companies featured in the report who are developing neuromodulation devices include Medtronic, Boston Scientific, St Jude Medical (Subsidiary of Abbott Diagnostics), Cyberonics (Subsidiary of LivaNova)

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

Read

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

Read

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

Read

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever